ImmunoplexTM enables needle-free, infectious agent-free immune complex vaccines, as well as autologous cellular oncology vaccines.
ImmunoplexTM is a platform technology aimed at transforming the $26B global vaccine market by delivering cost effective needle-free immune complex vaccines without side effects. The crux of the invention includes a proprietary tag and an antibody that create immune complexes in a universal fashion. Proof of concept has been achieved in HepB, influenza, and breast cancer. Memcine will function as a discovery engine for the pharma industry.